Ann: Update on US FDA De Novo Classification Request, page-236

Respiratiory Monitoring Sector News of Interest for RAP Holders:

There was an Interesting announcement from Respiri after market today today.

WHEEZOS IN 3 CHINESE HOSPITALS

Respiri Ltd (RSH) has agreed to a request by three hospitals in China to trial Wheezo's on patients admitted with heightened respiratory problems resulting from infection with the coronavirus COVID19

Three hospitals under the supervision of the Chongqing Municipal Health Commission have expressed their interest in using Respiri's wheezo device to help monitor the lung function of patients who have been admitted with the COVID19 virus.
"

Respiri's "Wheezo" can objectively monitor an Asthma or COPD patients wheeze (main symptom of asthma) + combines that with an app providing the full life cycle of patient data (symptoms, triggers, medication, environmental conditions) to provide the perfect complimentary tool for patients in between doctor and hospital visits.

coronavirus just like the common cold acts as a trigger for an asthmatics asthma - as such the current environment requires extra caution from asthmatics globally.

Today also the WHO and CDC highlighted the risk from COVID19 for people with chronic health conditions such as

- Asthma
- Blood pressure / heart disease
- Diabetes

The interesting thing about this list above is Asthma is the only one which doesn't have objective digital based symptom monitors widely available to patients - It could be the perfect time for Respiri to launch its Wheezo product in Q4 this year.


The market cap of ~$40m looks light to me, given the company will launch its product Q4 this year, and has a target market of ~ 350m asthma patients globally. CE+TGA already achieved, FDA on the way.

Given all the hype about CV, this stock hasn't been viewed as a beneficiary of the Corova Virus outbreak - maybe news will get out and it could start to catch a bid tomorrow?

Appreciate any thoughts/views?